drugset / Trial / NCT07714317
Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this phase Ib/II multicenter randomized control study is to investigate the efficacy and safety of peri-operative treatment with combination of CTLA-4, PD-1 antibodies and bevacizumab in resectable HCC
Timeline
- Start
- 2026-07-20
- Primary completion
- 2027-07-31
- Completion
- 2030-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | IBI310 | Monoclonal antibody | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |